Voting Rights and Shares Capital of the Company
Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of April 30, 2025. The company disclosed having 47,426,851 shares outstanding, with 49,535,883 theoretical voting rights and 49,513,765 exercisable voting rights. This regular monthly disclosure is required by French regulatory authorities for companies listed on Euronext Paris.
Nanobiotix (NBTX) ha comunicato il suo ultimo stato dei diritti di voto e del capitale sociale al 30 aprile 2025. La società ha dichiarato di avere 47.426.851 azioni in circolazione, con 49.535.883 diritti di voto teorici e 49.513.765 diritti di voto esercitabili. Questa comunicazione mensile regolare è richiesta dalle autorità regolatorie francesi per le società quotate su Euronext Paris.
Nanobiotix (NBTX) ha informado su su último estado de derechos de voto y capital social al 30 de abril de 2025. La compañía declaró tener 47.426.851 acciones en circulación, con 49.535.883 derechos de voto teóricos y 49.513.765 derechos de voto ejercibles. Esta divulgación mensual regular es requerida por las autoridades regulatorias francesas para las empresas que cotizan en Euronext París.
Nanobiotix (NBTX)는 2025년 4월 30일 기준 최신 의결권 및 주식 자본 현황을 보고했습니다. 회사는 47,426,851주의 발행 주식과 49,535,883개의 이론적 의결권, 그리고 49,513,765개의 행사 가능한 의결권을 보유하고 있다고 밝혔습니다. 이 정기 월간 공개는 유로넥스트 파리(Euronext Paris)에 상장된 기업에 대해 프랑스 규제 당국이 요구하는 사항입니다.
Nanobiotix (NBTX) a communiqué son dernier état des droits de vote et du capital social au 30 avril 2025. La société a déclaré détenir 47 426 851 actions en circulation, avec 49 535 883 droits de vote théoriques et 49 513 765 droits de vote exerçables. Cette divulgation mensuelle régulière est exigée par les autorités réglementaires françaises pour les entreprises cotées sur Euronext Paris.
Nanobiotix (NBTX) hat seinen aktuellen Stand der Stimmrechte und des Aktienkapitals zum 30. April 2025 gemeldet. Das Unternehmen gab an, 47.426.851 ausstehende Aktien zu haben, mit 49.535.883 theoretischen Stimmrechten und 49.513.765 ausübbaren Stimmrechten. Diese regelmäßige monatliche Offenlegung ist von den französischen Aufsichtsbehörden für Unternehmen, die an der Euronext Paris notiert sind, vorgeschrieben.
- None.
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, May 14, 2025 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| April 30, 2025 | 47,426,851 | 49,535,883 | 49,513,765 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Ricky Bhajun Director, Investor Relations investors@nanobiotix.com | |
| Media Relations | ||
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com | |
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachments
FAQ
What is the current number of outstanding shares for Nanobiotix (NBTX) as of April 2025?
How many voting rights does Nanobiotix (NBTX) have as of April 2025?
What is the difference between theoretical and exercisable voting rights for NBTX?
Where is Nanobiotix (NBTX) stock listed?
